StockData
Oculis Holding AG logo

Oculis Holding AG (OCS) company profile

OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 4, 2026Score 1/30
$7.51−0.12 (-1.57%)

Close on Nov 17, 2026Market cap $451.27MP/E –Yield –

About Oculis

Pharmaceutical Preparations, SIC 2834

Oculis Holding AG operates as a clinical-stage biopharmaceutical organization engaged in the discovery, research, and development of pharmaceutical product candidates. The enterprise conducts preclinical evaluations, clinical trials, and regulatory compliance activities to advance medical treatments based on its scientific technology and in-licensed assets. It focuses on advancing a pipeline of candidate therapies toward commercial readiness and manufacturing. The company's intended recipients and end users include patient groups with targeted therapeutic needs, while its direct commercial relationships involve academic institutions, healthcare entities, and corporate research partners.

The enterprise is headquartered in Zug, Switzerland, where its principal executive offices are situated. Its geographic presence and operating footprint include facilities and corporate activities located across Switzerland, Iceland, and the United States. Additionally, the organization conducts cooperative scientific work through research and licensing partnerships with external international institutions.

Summary of the business section of Oculis's latest annual report, written by StockData.

Company profile

Company

Legal name
Oculis Holding AG
Headquarters
Zug, V8
Address
Bahnhofstrasse 7 6300
Phone
(617) 937-2423
Website
oculis.com
Employees
60, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
V8
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers SA, Lausanne, Switzerland

Stock & identifiers

Ticker
OCS
Other tickers
OCSAW
Exchange
Nasdaq
IPO date
Jun 2, 2023
Shares outstanding
60M, Dec 31, 2025
Filer category
Large accelerated filer
SEC CIK
1953530
FIGI
BBG01BJ1BHZ3
Share class FIGI
BBG01BJ1BJ07
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Oculis's leadership is listed in its proxy statement (Form DEF 14A).

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 2, 2023
Offer price
$11.50
Exchange
Nasdaq
Lock-up ends (est.)
Nov 29, 2023

“The public offering price is $11.50 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 60 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?